18F-FDG PET/CT监测转移性基底细胞癌对PD-1阻断治疗的应答
一例73岁女性转移性基底细胞癌患者,肿瘤突变负荷为111 mutations/Mb,经手术及辅助放疗后复发,sonidegib仅短暂稳定病情,后接受超适应症pembrolizumab治疗,系列FDG PET/CT显示肿瘤代谢在12个月内逐渐下降并达到完全代谢缓解。
要点
- 转移性基底细胞癌经PD-1抑制剂pembrolizumab治疗后,FDG PET/CT可监测到代谢逐渐下降至完全代谢缓解。
- 该患者肿瘤突变负荷为111 mutations/Mb,sonidegib仅短暂稳定疾病。
- FDG PET/CT系列显像可用于评估PD-1阻断治疗的代谢应答。
核心结论
- FDG PET/CT系列显像显示转移性基底细胞癌对pembrolizumab治疗逐渐出现代谢下降,最终达到完全代谢缓解。
研究设计与样本
- 个案报道:一例73岁女性转移性基底细胞癌患者,肿瘤突变负荷111 mutations/Mb,接受T12椎体切除及T10-L3后路脊柱融合术和辅助放疗后复发。
主要发现
- sonidegib治疗仅短暂稳定疾病,后超适应症使用pembrolizumab,系列FDG PET/CT显示肿瘤代谢在12个月内逐渐下降并达到完全代谢缓解。
临床怎么用
- 对于转移性基底细胞癌接受PD-1抑制剂治疗的患者,可考虑系列FDG PET/CT监测代谢应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 73-year-old woman with history of metastatic basal cell carcinoma presented with a large spinal mass demonstrating a high mutational burden of 111 mutations/Mb. She underwent T12 corpectomy and T10-L3 posterior spinal fusion followed by adjuvant radiation. After 2 years of surveillance, FDG PET/CT and a contrast-enhanced MRI revealed recurrence, prompting salvage therapy with the hedgehog signaling pathway inhibitor, sonidegib, which only transiently stabilized the disease. An off-label treatment with the programmed death protein 1 inhibitor, pembrolizumab, was initiated. Serial FDG PET/CT showed gradual decline in tumor metabolism over the next 12 months, leading to complete metabolic response.
引用
- Jadvar H, In GK. 18F-FDG PET/CT Monitoring of Response to Programmed Death Protein 1 Blockade in Metastatic Basal Cell Carcinoma. Clin Nucl Med. 2021. PMID: 33512957. doi:10.1097/RLU.0000000000003528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。